Breast Cancer Female(LaPBrecon)NCT07006662
Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction
An observational study of Breast Cancer Female, run by University Hospitals of North Midlands NHS Trust at 1 site in United Kingdom.
Trial summary
The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer Female
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Aug 2026to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The trial will be carried out at University Hospitals of North Midlands (UHNM). This will be a single centre study. Patients will be screened by the breast surgery Team for the eligibility criteria and recruited from the Breast Outpatients Clinic and marking of the perforators will be carried out on admission unit.
Who may be able to join
- Patients undergoing elective breast surgery
- Age ≥ 18 years
- Female
- BMI ≤ 30 kg/m2
- Willing and able to give fully informed consent,
- Willing and able to comply with the study procedures
Who cannot join
- Pregnant patients
- Previous bilateral Breast or axillary surgery
- Undergoing bilateral oncoplastic procedure or requiring bilateral pre-operative marking
- Undergoing breast surgery requiring pre-operative marking of some of the landmarks and has had contralateral breast or axillary surgery in the past
- Surgery planned within 24 hours of screening for eligibility
- Known history of allergy or contact dermatitis to ultrasound gels
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
University Hospitals of North Midlands NHS Trust
Stoke-on-Trent, ST4 6QG
Aviva Ogbolosingha, 01782 ext. 675380, aviva.ogbolosingha@uhnm.nhs.uk
About this study
Official title: Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction (LaPBrecon)
The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.
Read the detailed description
Breast conserving surgery is commonly performed in patients with breast cancer. It is important to fill the defect from a breast conserving procedure to achieve good cosmetic outcome. This defect can be filled either by using the adjacent breast tissue or by using perforator flaps; commonly taken from the area posterolateral to the breast or or below the inframammary crease. These perforator flaps can be based on thoracodorsal artery, lateral thoracic artery, lateral intercostal artery or the medial intercostal artery. The identification of these perforators using a hand-held doppler is an important but time-consuming intraoperative step. Surgeons often use the information derived from cadaveric studies when identifying these perforators as there is minimal information on the location of these perforators in relation to anatomical landmarks.
Patients with a BMI of < 25 Kg/m2admitted for elective breast surgery or attending breast outpatients' clinic will be included in the study. Patients will be sent information about this study prior to admission or the clinic appointment with a copy of the consent form. Participants will have a 30-minute assessment using a hand held doppler and perforators will be mapped against soft tissue and bony landmarks. Data will be analysed to identify common anatomical locations for the different chest wall perforators.
- Conditions
- Breast Cancer Female
What is being measured
The primary outcome is the main question the study is designed to answer.
Location of vesselse
The location of the AICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Measured: 6 months
Location of vessels
The location of the MICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Measured: 6 months
Location of vessels
The location of the LTAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Measured: 6 months
Location of vessels
The location of the LICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Measured: 6 months
Secondary outcomes (1)
Variability
The degree of variability in location of the perforators.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study start4 Aug 2026
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer FemaleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospitals of North Midlands NHS Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07006662
- Sponsor's protocol ID
- 3427
- Acronym
- (LaPBrecon)
- Status last verified
- Sep 2026
- First submitted
- 27 May 2025
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction (LaPBrecon)
- ClinicalTrials.gov ID
- NCT07006662
- Acronym / sponsor ID
- (LaPBrecon) / 3427
- Conditions
- Breast Cancer Female
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University Hospitals of North Midlands NHS TrustUniversity, hospital or other
- Study start
- 4 Aug 2026 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.
Detailed description
Breast conserving surgery is commonly performed in patients with breast cancer. It is important to fill the defect from a breast conserving procedure to achieve good cosmetic outcome. This defect can be filled either by using the adjacent breast tissue or by using perforator flaps; commonly taken from the area posterolateral to the breast or or below the inframammary crease. These perforator flaps can be based on thoracodorsal artery, lateral thoracic artery, lateral intercostal artery or the medial intercostal artery. The identification of these perforators using a hand-held doppler is an important but time-consuming intraoperative step. Surgeons often use the information derived from cadaveric studies when identifying these perforators as there is minimal information on the location of these perforators in relation to anatomical landmarks.
Patients with a BMI of < 25 Kg/m2admitted for elective breast surgery or attending breast outpatients' clinic will be included in the study. Patients will be sent information about this study prior to admission or the clinic appointment with a copy of the consent form. Participants will have a 30-minute assessment using a hand held doppler and perforators will be mapped against soft tissue and bony landmarks. Data will be analysed to identify common anatomical locations for the different chest wall perforators.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The trial will be carried out at University Hospitals of North Midlands (UHNM). This will be a single centre study. Patients will be screened by the breast surgery Team for the eligibility criteria and recruited from the Breast Outpatients Clinic and marking of the perforators will be carried out on admission unit.
Key inclusion criteria (6 listed)
- Patients undergoing elective breast surgery
- Age ≥ 18 years
- Female
- BMI ≤ 30 kg/m2
- Willing and able to give fully informed consent,
Key exclusion criteria (6 listed)
- Pregnant patients
- Previous bilateral Breast or axillary surgery
- Undergoing bilateral oncoplastic procedure or requiring bilateral pre-operative marking
- Undergoing breast surgery requiring pre-operative marking of some of the landmarks and has had contralateral breast or axillary surgery in the past
- Surgery planned within 24 hours of screening for eligibility
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Location of vesselse
Time frame: 6 months
The location of the AICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Location of vessels
Time frame: 6 months
The location of the MICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Location of vessels
Time frame: 6 months
The location of the LTAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
Location of vessels
Time frame: 6 months
The location of the LICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks
1 secondary outcome
Variability
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
Related trials for Breast Cancer Female
Not yet recruitingObservational study
DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
Renal Impairment, Digestive Cancers
RecruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
RecruitingEarly Phase 1
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
PDL1 Gene Mutation, Non Small Cell Lung Cancer
Active, not recruitingPhase 1
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Advanced Cancer, Advanced Malignancies
RecruitingPhase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer Female, run by University Hospitals of North Midlands NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aviva Ogbolosingha (01782675380, aviva.ogbolosingha@uhnm.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Location of vesselse (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.